Chantelle Wilcox

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

James W. Denham, Allison Steigler, Chantelle Wilcox et al. · The Lancet Oncology · 2008 · 96 citations

Medicine, Oncology, Urology +17

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial

James W. Denham, Chantelle Wilcox, David Joseph et al. · The Lancet Oncology · 2012 · 53 citations

Medicine, Oncology, Pharmacotherapy +14

Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point

Brett Delahunt, David S. Lamb, John R. Srigley et al. · Pathology · 2010 · 47 citations

Medicine, Pathology, Urology +5

Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer

James W. Denham, Chantelle Wilcox, David S. Lamb et al. · Radiotherapy and Oncology · 2012 · 39 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Androgen Deprivation Therapy for Prostate Cancer Does Not Increase Cardiovascular Mortality in the Long Term

Chantelle Wilcox, Allison Kautto, Allison Steigler et al. · Oncology · 2012 · 31 citations

Medicine, Oncology, Radiation Oncology +17